Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RNF4 | P78317 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575071 | 0.84 | MAPT (0.41) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL27857005 | 0.83 | ELANE (0.37) | MAPTATML3MBTL1ALDH1A1USP2 | |
| SCHEMBL10025073 | 0.83 | MAPT (0.46) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL8646552 | 0.83 | THRB (0.47) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL22341330 | 0.82 | HSD17B10 (0.49) | ALOX15HSD17B10HTTKMT2AUSP2 | |
| SCHEMBL6895096 | 0.81 | MAPT (0.44) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL10025075 | 0.81 | MAPT (0.44) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL322125 | 0.81 | MAPT (0.44) | MAPTTDP1KDM4EATML3MBTL1 | |
| SCHEMBL22228973 | 0.80 | MGLL (0.41) | MAPTL3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL9353461 | 0.79 | TDP1 (0.54) | MAPTTDP1KDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359419-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | Pharmacytics B.V. (NL) | 2024-05-01 | — | — | EP | claimed |
| CN-117871750-A | Method for determining content of lysine | 兰州大学 | 2024-04-12 | — | — | CN | claimed |
| CN-117858882-A | Prodrugs having 1- (disulfanyl) alkoxy-carbonyl units | 药物有限公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2022271018-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | PHARMACYTICS B.V. (NL) | 2022-12-29 | — | — | WO | claimed |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024163262-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240217936-A1 | 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4359419-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | Pharmacytics B.V. (NL) | 2024-05-01 | — | — | EP | disclosed |
| CN-117871750-A | Method for determining content of lysine | 兰州大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5559266-A | Iodinated esters | NYCOMED IMAGING AS (NO) | 1996-09-24 | — | — | US | disclosed |
| US-5416223-A | Iodinated esters | NYCOMED IMAGING AS (NO) | 1995-05-16 | — | — | US | disclosed |
| US-5370861-A | Iodinated esters contrast medium and use | NYCOMED IMAGING AS (NO) | 1994-12-06 | — | — | US | disclosed |
| EP-0452377-B1 | IODINATED ESTERS | NYCOMED IMAGING AS (NO) | 1994-09-21 | — | — | EP | disclosed |
| EP-0452377-A1 | IODINATED ESTERS. | HOLMES MICHAEL JOHN (GB) | 1991-10-23 | — | — | EP | disclosed |
| WO-1990007491-A1 | IODINATED ESTERS | NYCOMED AS (NO) | 1990-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DNTT, NAPRT, NAMPT | MAPT 1204/4885TDP1 254/4885KDM4E 1822/4885 |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | EBP, SIGMAR1, EP300 | MAPT 703/4885TDP1 3572/4885KDM4E 1490/4885 |
| US-20240217936-A1 | 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, WASF2, CYP3A5 | MAPT 3634/4885TDP1 4531/4885KDM4E 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.